Venous Thromboembolism - Market Insights & Drugs Sales Forecast (VTE) - 2020

  • ID: 3693112
  • Drug Pipelines
  • Region: Global
  • 100 pages
  • DelveInsight
1 of 3
Global VTE Market Was $4.2 Billion in 2015 and Expected to Grow to $4.75 Billion by 2020
The Venous Thromboembolism- Market Insights & Drugs Sales Forecast (VTE) -2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan.

Globally the overall incidence for Venous Thromboembolism (VTE) is increasing at a higher rate. For VTE, there are approximately 1 million cases in the United States each year, many of which represent recurrent disease. The increasing epidemiology of venous thromboembolism is a key driver for the global anticoagulants market.

Key Coverage and Benefits:

- The report will help in developing business strategies by understanding the trends shaping and driving the global Venous Thromboembolism (VTE) market.
- Identifying patient populations in the global Venous Thromboembolism (VTE) market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the best opportunities for Venous Thromboembolism (VTE) therapeutics in each of the markets covered.
- To understand the future market competition in the global Venous Thromboembolism (VTE) therapeutics market and Insightful review of the key market drivers and barriers.

Scope of the Report:

- Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2020.
- It also provides Venous Thromboembolism (VTE) for United States, EU5 and Japan from 2015 and forecasted Market to 2020.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Executive Summary
- Market Share of Anticoagulants in 2015 and 2020
- Worldwide Market Share of Anticoagulants in 2015
- Worldwide Market Share of Anticoagulants in 2020

Chapter 1 Anticoagulants Introduction
- Warfarin
- Low Molecular Weight Heparins
- New Oral Anticoagulants (NOAC)

Chapter 2 Venous Thromboembolism
- Disease Overview
- Epidemiology of Venous Thromboembolism
- Treatment Landscape
- Treatment Algorithm
- Treatment Goals
- Treatment Details

Chapter 3 Key Marketed Anticoagulants
- Novel Oral Anticoagulants Comparison
- Reversal Agents (Antidotes)

Chapter 4 Anticoagulants Market Assessment by VTE
- Key Findings
- Global Anticoagulants Market Sales by Venous Thromboembolism
- Global Anticoagulants Market Share (%) in Venous Thromboembolism

Chapter 5 United States Anticoagulants Market Assessment
- Key Findings
- United States Anticoagulants Market Sales by Venous Thromboembolism
- United States Anticoagulants Market Share (%) in Venous Thromboembolism

Chapter 6 Europe 5 Anticoagulants Market Assessment
- Key Findings
- Europe 5 Anticoagulants Market Sales by Venous Thromboembolism
- Europe 5 Anticoagulants Market Share (%) in Venous Thromboembolism

Chapter 7 Japan Anticoagulants Market Assessment
- Key Findings
- Japan Anticoagulants Market Sales by Venous Thromboembolism
- Japan Anticoagulants Market Share (%) in Venous Thromboembolism

Chapter 8 Xarelto (rivaroxaban) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy of Xarelto
- Safety of Xarelto
- Side effects of Drugs
- Cost of Therapy
- Global Drug Sales
- Xarelto Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Xarelto Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trials Information
- SWOT Analysis of Xarelto

Chapter 9 Pradaxa (dabigatran etexilate mesylate) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy of Pradaxa
- Safety of Pradaxa
- Side effects of Drugs
- Cost of Therapy
- Global Drug Sales
- Pradaxa Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Pradaxa Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trial Information
- SWOT Analysis of Pradaxa

Chapter 10 Eliquis(Apixaban) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy and Safety of Eliquis
- Side effects of Eliquis
- Cost of Therapy
- Global Drug Sales
- Eliquis Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Eliquis Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trial Information
- SWOT Analysis of Eliquis

Chapter 11 Savaysa (edoxaban tosylate) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy of Savaysa
- Safety of Savaysa
- Side Effects of Savaysa
- Cost of Therapy
- Global Drug Sales
- Savaysa Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Savaysa Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trial Information
- SWOT Analysis of Savaysa

Chapter 12 Lovenox (enoxaparin) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Safety and Efficacy of Lovenox
- Side effects of Lovenox
- Cost of Therapy
- Global Drug Sales
- Lovenox Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication (20%)
- Lovenox Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trial Information
- SWOT Analysis of Lovenox

Chapter 13 Fraxiparine
- Product Profile
- Advantages & Disadvantages
- Safety and Efficacy of Fraxiparine
- Side effects of Drugs
- Cost of Therapy
- Global Drug Sales
- Fraxiparine Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Fraxiparine Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trials Information
- SWOT Analysis of Fraxiparine

Chapter 14 Arixtra (Fondaparinux) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy of Arixtra
- Safety of Arixtra
- Side effects of Drugs
- Cost of Therapy
- Global Drug Sales
- Arixtra Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Arixtra Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trial Information
- SWOT Analysis of Arixtra

Chapter 15 Betrixaban Drug Profile
- Product Profile
- Advantages & Disadvantages
- Safety and Efficacy
- Side effects of Drugs
- Expected Cost of Therapy
- Global Drug Sales
- Betrixaban Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Betrixaban Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trials Information

Chapter 16 Market Drivers and Constraints
- Factors Driving the Market Growth
- Factors Constraining the Market Growth
- Consulting Services
- Disclaimer

List of Tables
- Table 1 Key Marketed Anticoagulants
- Table 2 Comparison of NOACs & Warfarin
- Table 3 Global Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
- Table 4 Global Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
- Table 5 US Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
- Table 6 US Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
- Table 7 EU5 Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
- Table 8 EU5 Anticoagulants Sales in Venous Thromboembolism – 2015-2020 (USD MM)
- Table 9 Japan Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
- Table 10 Japan Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
- Table 11 Xarelto Historical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 12 Xarelto Sales by Venous Thromboembolism (VTE) (USD MM)
- Table 13 Xarelto, Clinical Trials by Zone, 2016
- Table 14 Pradaxa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 15 Pradaxa Sales by Venous Thromboembolism (VTE) (USD MM)
- Table 16 Pradaxa, Clinical Trials by Zone, 2016
- Table 17 Eliquis Historical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 18 Eliquis Sales by Venous Thromboembolism (VTE) (USD MM)
- Table 19 Eliquis, Clinical Trials by Zone, 2016
- Table 20Savaysa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 21 SavaysaSales by Venous Thromboembolism (VTE) (USD MM)
- Table 22 Savaysa, Clinical Trials by Zone, 2016
- Table 23 LovenoxHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 24 LovenoxSales by Venous Thromboembolism (VTE) (USD MM)
- Table 25 Lovenox, Clinical Trials by Zone, 2016
- Table 26 FraxiparineHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 27 FraxiparineSales by Venous Thromboembolism (VTE) (USD MM)
- Table 28 Fraxiparine, Clinical Trials by Zone, 2016
- Table 29 ArixtraHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 30 ArixtraSales by Venous Thromboembolism (VTE) (USD MM)
- Table 31 Arixtra, Clinical Trials by Zone, 2016
- Table 32 BetrixabanForecasted Sales (2011-2020)(USD MM)
- Table 33 BetrixabanSales by Venous Thromboembolism (VTE) (USD MM)
- Table 34 Betrixaban, Clinical Trials by Zone, 2016

List of Figures
- Figure 1 Global Anticoagulants Sales in Venous Thromboembolism- 2011-2020
- Figure 2 Global Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
- Figure 3 US Anticoagulants Sales in Venous Thromboembolism- 2011-2020
- Figure 4 US Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
- Figure 5 EU5 Anticoagulants Sales in Venous Thromboembolism- 2011-2020
- Figure 6 EU5 Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
- Figure 7 Japan Anticoagulants Sales in Venous Thromboembolism- 2011-2020
- Figure 8 Japan Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
- Figure 9 Xarelto Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 10 Xarelto Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 11 Xarelto, Clinical Trials by Zone (%), 2016
- Figure 12 Pradaxa Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 13 Pradaxa Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 14 Pradaxa, Clinical Trials by Zone (%), 2016
- Figure 15 Eliquis Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 16 Eliquis Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 17 Eliquis, Clinical Trials by Zone (%), 2016
- Figure 18 SavaysaHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 19 Savaysa Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 20 Savaysa, Clinical Trials by Zone (%), 2016
- Figure 21 Lovenox Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 22 Lovenox Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 23 Lovenox, Clinical Trials by Zone (%), 2016
- Figure 24 Fraxiparine Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 25 Fraxiparine Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 26 Fraxiparine, Clinical Trials by Zone (%), 2016
- Figure 27 ArixtraHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 28 Arixtra Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 29 Arixtra, Clinical Trials by Zone (%), 2016
- Figure 30 BetrixabanForecasted Sales (2011-2020) (USD MM)
- Figure 31 Betrixaban Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 32 Betrixaban, Clinical Trials by Zone (%), 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll